Drug Abuse, Depression and Responses to HIV Counseling

药物滥用、抑郁症和艾滋病毒咨询的反应

• 批准号: 6627789
• 负责人: MICHAEL MARMOR
• 金额: $ 66.7万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6627789
• 关键词: AIDS education /prevention; HIV infections; behavioral /social science research tag; blood tests; bupropion; clinical trials; combination therapy; communicable disease transmission; comorbidity; counseling; depression; disease /disorder proneness /risk; drug abuse; high risk behavior /lifestyle; homosexuals; human immunodeficiency virus 1; human subject; human therapy evaluation; longitudinal human study; mental disorder chemotherapy; outcomes research; patient oriented research; serotyping; sex behavior; statistics /biometry; substance abuse related behavior

DESCRIPTION: (provided by applicant) The long-term objective of this research is to reduce the incidence of infection with human immunodeficiency virus type 1 (HIV) in industrialized countries by developing methods to identify and treat high-risk individuals whose response to HIV testing and counseling is hindered by psychopathology. The project's specific aims are (1) to describe the distribution of psychopathologies among persons undergoing HIV testing and counseling, and (2) to test the hypotheses that high-risk, HIV-seronegative persons with mild-to-moderate depression will be more likely to adopt protective behavior changes when provided with pharmacotherapy for their depression than when treated with placebo. The study design to achieve specific aim 2 will be a randomized, double-blinded clinical trial of bupropion hydrochloride versus placebo administered for a total of 7 months. The study population will be initially high-risk, HIV-seronegative men who have sex with men (MSM). Individuals who are ineligible or decline entry into the clinical trial will be entered into an observational study. The primary outcome measure of the clinical trial will be self-reported numbers of partners in unprotected receptive anal intercourse. Secondary outcomes will be substances used and frequency of substance use by self-report and toxicology; (c) new infections with sexually transmitted infections including gonorrhea, syphilis, Kaposi's sarcoma-associated herpesvirus, and hepatitis C virus (HCV) and HIV; and (d) measures of psychological factors that have been shown to be, or are thought to be, associated with HIV incidence rates, including measures of self-efficacy, self-esteem, stage of change, and depression. Enrollment data from the observational study will be combined with enrollment data from the clinical trial to provide a description of the distribution of psychopathologies and substance abuse among high-risk MSM. Longitudinal data form the observational study will be used to assess the associations of psychopathologies, substances used and frequency of substance use with adverse outcomes.

描述：（由申请人提供）这项研究的长期目标 是为了减少人类免疫缺陷病毒类型感染的发生率 工业化国家的1（艾滋病毒）通过开发识别和治疗的方法 高风险的人对艾滋病毒测试和咨询的反应受到阻碍 通过心理病理学。该项目的具体目的是（1）描述 在接受艾滋病毒测试和 咨询和（2）检验高风险，艾滋病毒智力的假设 轻度到中度抑郁的人更有可能采用 在为其药物治疗提供时，保护行为会改变 抑郁症比安慰剂治疗时。研究设计以实现特定 AIM 2将是一个随机，双盲的安非他酮临床试验 盐酸盐与安慰剂总共施用了7个月。研究 人口最初将是高风险的艾滋病毒，艾滋病毒的男人 男人（MSM）。没有资格或拒绝进入临床的个人 试验将进入观察性研究。主要结果度量 临床试验将是自我报告的无保护的伴侣 接受肛门性交。次要结果将是使用的物质， 自我报告和毒理学使用物质的频率； （c）新感染 带有性传播感染，包括淋病，梅毒，卡波西的感染 肉瘤相关的疱疹病毒，丙型肝炎病毒（HCV）和HIV； （d） 已经证明是或被认为是的心理因素的度量 是，与艾滋病毒的发病率相关，包括自我效能的度量， 自尊，变化阶段和沮丧。来自 观察性研究将与临床的注册数据结合 试验以说明心理病理的分布和 高风险MSM的药物滥用。纵向数据构成观测 研究将用于评估心理病理学，物质的关联 使用和使用不良结果的物质使用频率。